Granted Patent B2

US 12,496,349 · App. 17/288,814 · Granted Dec 16, 2025

Inventors: Dong Wang (Omaha, NE); Steven R. Goldring (Auburndale, MA); Gang Zhao (Omaha, NE); Rongguo Ren (Omaha, NE); Zhenshan Jia (Omaha, NE); Xin Wei (Omaha, NE)

Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA

A61K47/58A61K47/6903

Abstract

Claims (55)

1 . A thermoresponsive polymer-drug conjugate, comprising a hydrophobic drug molecule moiety covalently bonded to a water-soluble polymer carrier, wherein the polymer-drug conjugate comprises a plurality of repeating unit (A) and a plurality of repeating unit (B):

wherein:

R 1 and R 2 are independently H, methyl, or halogen;

R 3 is a C 1 -C 8 alkyl substituted by one, two, or three OH groups ;

X is a moiety of a drug molecule, or a pharmaceutically acceptable salt thereof;

L is a linker covalently connecting the drug molecule moiety X to the polymer backbone through Y;

Y is a functional group which, together with a part of the drug molecule moiety X or a part of the linker moiety L, forms an acid labile functional group that can be hydrolyzed under physiological conditions to release the drug molecule;

and

Z is NH or O;

wherein the polymer-drug conjugate is soluble in water at a first temperature and forms a prodrug hydrogel at a second temperature which is higher than the first temperature, wherein the second temperature is at least 28° C., and wherein the content of the hydrophobic drug moiety in the polymer-drug conjugate is 12% by weight or higher.

2 . The thermoresponsive polymer-drug conjugate of claim 1 , wherein the polymer carrier is a copolymer comprising N-(2-hydroxypropyl)methacrylamide monomer units.

3 . The thermoresponsive polymer-drug conjugate of claim 1 , wherein:

R 1 and R 2 each H or methyl;

R 3 is C 2 -C 5 alkyl substituted by one or two OH groups;

L is —[NH(CH 2 ) i C(O)] j —, —NH(CH 2 ) k —, —NH(CH 2 ) k -T-(CH 2 ) p —, —NH(CH 2 ) k (NHC(O)—, —NH(CH 2 ) k NH—(CH 2 ) p -T-(CH 2 ) q —C(O)—, or —NH(CH 2 )(NHC(O)—(CH 2 ) p -T-(CH 2 ) q —C(O)—, wherein T is C 6 -C 10 arylene, C 3 -C 8 cycloalkylene, 5- to 10-membered heteroarylene, or 5- to 10-membered heterocycloalkylene, wherein I is an integer selected from 1 to 6; j is integer selected from 1 to 4; k is an integer selected from 1 to 10; p is 0, 1, 2, or 3; and q is 0, 1, 2, or 3;

Y is O, NH, or NH—N═, wherein “═” is a double bond;

and

Z is NH.

4 . The thermoresponsive polymer-drug conjugate of claim 3 , wherein:

i is 1 or 2;

j is 1, 2, or 3;

k is an integer selected from 1 to 6;

p is 0, 1, or 2; and

q is 0, 1, or 2.

5 . The thermoresponsive polymer-drug conjugate of claim 1 , wherein:

L is —[NHCH 2 C(O)] j —, —NH(CH 2 )k, —NH(CH 2 ) k -T-CH 2 —or —NH(CH 2 )(NHC(O)-T-C(O)—, wherein T at each occurrence is independently C 6 -C 10 arylene or 5- to 10-membered heteroarylene; j is 2 or 3; and k is 2, 3, or 4.

6 . The thermoresponsive polymer-drug conjugate of claim 1 , wherein:

R 1 and R 2 are each methyl;

R 3 is a —CH 2 CH(OH)CH 3 ;

L is —NHCH 2 C(O)NHCH 2 C(O)—, —NH(CH 2 ) 3 —,

Y is O, NH, or NH—N═;

and

Z is NH.

7 . The thermoresponsive polymer-drug conjugate of claim 1 , wherein the drug molecule is selected from the group consisting of: glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDS), analgesics, bone anabolic agents, antioxidants, anti-cancer agents, hormones, and antibiotics.

8 . The thermoresponsive polymer-drug conjugate of claim 1 , wherein the drug molecule is selected from the group consisting of dexamethasone, tanshinone IIA, progesterone, estradiol, curcumin, hydromorphone, sinomenine, and apigenin.

9 . The thermoresponsive polymer-drug drug conjugate of claim 1 , wherein:

the repeating unit (A) is an N- (2-hydroxypropyl)methacrylamide monomer having a structure of formula:

and

the repeating unit (B) has a structure selected from the group consisting of:

10 . The thermoresponsive polymer-drug conjugate of claim 9 , wherein the repeating unit (B) has the structure:

wherein the dexamethasone content of the polymer-drug conjugate is in the range of 15-40% by weight, and wherein the molecular weight of the polymer-drug conjugate is in the range of 1-45 kDa.

11 . A pharmaceutical composition comprising a thermoresponsive polymer-drug conjugate of claim 10 and one or more pharmaceutically acceptable carriers and/or excipients, wherein the concentration of the polymer drug-conjugate in the composition is in the range of 10-50% w/v.

12 . The thermoresponsive polymer-drug conjugate of claim 9 , wherein the repeating unit (B) has the structure:

wherein the tanshinone IIA content of the polymer-drug conjugate is in the range of 12-40% by weight; and wherein the molecular weight of the polymer-drug conjugate is in the range of 1-45 kDa.

13 . A pharmaceutical composition comprising a thermoresponsive polymer-drug conjugate of claim 12 and one or more pharmaceutically acceptable carriers and/or excipients, wherein the concentration of the polymer drug-conjugate in the composition is in the range of 10-50% w/v.

14 . A pharmaceutical composition comprising a thermoresponsive polymer-drug conjugate of claim 1 and one or more pharmaceutically acceptable carriers and/or excipients.

15 . The thermoresponsive polymer-drug conjugate of claim 1 , wherein the content of the hydrophobic drug moiety in the polymer-drug conjugate is 12% to 40% by weight.

16 . The thermoresponsive polymer-drug conjugate of claim 1 , wherein the content of the hydrophobic drug moiety in the polymer-drug conjugate is 15% or higher.

17 . The thermoresponsive polymer-drug conjugate of claim 1 , wherein the content of the hydrophobic drug moiety in the polymer-drug conjugate is 19% or higher.

18 . A method of treating a disease or disorder, comprising administration to a subject in need of treatment a therapeutically effective amount of a thermoresponsive polymer-drug conjugate of claim 1 , wherein the disease or disorder is rheumatoid arthritis, osteoarthritis, soft tissue inflammation and/or injury, periodontal bone loss, local infection and tissue abscess, delayed fracture union, neurological disorders, malignancies, regional pain, hearing loss, ischemic heart disease, heterotopic ossification, orthopaedic joint implant loosening, reproductive dysfunction, hormone administration for high risk pregnancy, or skin aging.

19 . The method of claim 18 , wherein the polymer-drug conjugate is administered through intra-articular, i ntradermal, intraperitoneal, intramuscular, intravitreal, intravaginal, intracranial, epidural, intracardiac, or musculoskeletal soft tissues, wherein the the polymer-drug conjugate is retained at tissue sites to slowly release active drug.

20 . The method of claim 18 , wherein the polymer-drug conjugate is formulated into a spray that can be applied to an open wound or surgical field, or applied to inflamed skin at sites of inflammation.

21 . A method of treating a disease or disorder, comprising administration to a subject in need of treatment a therapeutically effective amount of two or more polymer-drug conjugates according to claim 1 , wherein the two or more polymer-drug conjugates are optionally combined into one injection formula.

22 . The method of claim 21 , wherein the two or more polymer-drug conjugates are polymer-drug conjugates wherein the drug is selected from the group consisting of antibiotics, anti-inflammatoires and bone anabolic agents, and the two or more polymer-drug conjugates are combined together into a single formulation for the treatment of periodontitis and associated bone loss.

23 . The method of claim 21 , wherein the two or more polymer-drug conjugates are polymer-drug conjugates wherein the drug is an opioid and anti-inflammatory and wherein the two or more polymer-drug conjugates are combined into a single formulation for treatment of pain.

Assignments (2)

Continuity (2)

References Cited (60)